Gelesis Secures $22,000,000 New Financing

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    222 Berkeley St. Boston, MA 02116 USA
  • Company Description
    Gelesis is a Boston-based company developing a breakthrough treatment for obesity and other related co-morbidities.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    Proceeds from the financing will be used to support the continued clinical development of its lead product, Gelesis100, as well as advancing its pipeline product, Gelesis 200, into the clinic. $4 million of the amount includes the conversion of outstanding convertible promissory notes.
  • M&A Terms
  • Venture Investor

Trending on Xconomy